Thymulin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Thymulin

Also known as: FTS, Facteur Thymique Sérique, Serum Thymic Factor, Zn-FTS, ZnFTS, Thymic Factor, Circulating, metFTS, methionine-FTS, methionine-serum thymic factor, PAT (peptide analogue of thymulin)

Thymic peptide hormone (nonapeptide); zinc-dependent metallopeptide; immunomodulator

Research chemicalLast updated: October 19, 2026Based on 31 peer-reviewed studies

What it is

Thymulin is a zinc-dependent thymic hormone studied for its anti-inflammatory and pain-relieving properties, particularly in autoimmune conditions, neuropathic pain, and lung disease. It works by regulating T-cell activity and reducing pro-inflammatory signals. No FDA-approved therapeutic use; evidence comes from animal models and early laboratory research.

The scientific side

Thymulin is a nonapeptide hormone exclusively produced by thymic epithelial cells; its biological activity requires the presence of zinc (forming Zn-FTS, the active form). It promotes intra- and extrathymic T-cell differentiation and modulates multiple T-cell subsets. Thymulin suppresses pro-inflammatory cytokine production (IL-1α, IL-1β, IL-6, TNF-α, IL-17, IFN-γ) and inhibits the NF-κB and p38 MAPK signaling pathways. It also inhibits microglial activation in the spinal cord and brain. In the context of aging and cancer, thymulin suppresses myeloid cell-driven chronic inflammation and enhances antitumor T-cell immunity. Thymulin further acts as a hypophysiotropic peptide, influencing pituitary secretion of gonadotropins, growth hormone, prolactin, and TSH, and participates in bidirectional thymus–neuroendocrine communication. Its synthetic analogue PAT (peptide analogue of thymulin) retains anti-inflammatory and analgesic properties without the hyperalgesic effects seen at low thymulin doses.

Class: Thymic peptide hormone (nonapeptide); zinc-dependent metallopeptide; immunomodulator

Administration & storage

Administration
Intraperitoneal (PMID: 30851702171925638582784)Intramuscular — adenoviral vector (PMID: 166173011738971428501652)Intracerebroventricular (PMID: 171925632105936028501652)Intratracheal — nanoparticle-delivered plasmid (PMID: 32577505)Intrahypothalamic or intrapituitary stereotaxic injection (PMID: 16166812)In vitro addition to cell/tissue culture (PMID: 850805012639846)Oral (homeopathic dilution 5cH in drinking waterbroiler chickens) (PMID: 22226317)
Storage
No storage conditions for thymulin peptide preparations are described in the reviewed abstracts.
Cautions
At low (ng-range) local or systemic doses, thymulin has been reported to produce hyperalgesic effects and increase pro-inflammatory mediators in animal models — dose-dependent effects appear to reverse at higher doses.,No toxicity was reported in reviewed animal studies of lung disease even at high doses or when expressed by adenoviral vectors; however, systematic safety and toxicology data in humans are absent from the reviewed literature.,Zinc is required for biological activity; zinc deficiency abolishes thymulin activity, and the zinc-unbound form is biologically inactive.,Gene therapy vectors (adenoviral, nanoparticle-based) carry platform-specific risks that are not specific to thymulin and must be evaluated separately; CK30PEG DNA nanoparticles have been reported safe in a human phase I/II clinical trial for a different gene.,No human pharmacokinetic, pharmacodynamic, or dose-finding clinical trial data for exogenous thymulin peptide administration are described in the reviewed abstracts — extrapolation from animal data is not supported.,Sterile technique is essential for any injectable preparation.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification